Rocket Pharmaceuticals (RCKT) announced that the FDA has granted Regenerative Medicine Advanced Therapy designation to RP-A601, the company’s investigational adeno-associated virus-based gene therapy for the treatment of PKP2-arrhythmogenic cardiomyopathy.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCKT:
- Cautious Hold Rating on Rocket Pharmaceuticals Amid IND Clearance and Clinical Hold Challenges
- Rocket Pharmaceuticals receives FDA clearance of RP-A701
- Rocket Pharmaceuticals Holds Annual Stockholders Meeting
- Rocket Pharmaceuticals price target lowered to $5 from $12 at UBS
- Optimistic Buy Rating for Rocket Pharmaceuticals Despite Gene Therapy Concerns